The role of secretory phospholipases as therapeutic targets for the treatment of myocardial ischemia reperfusion injury

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Sriram Ravindran, Gino A Kurian

Abstract

Myocardial reperfusion injury is a consequence of restoration of blood flow post ischemia. It is a complex process involving an acute inflammatory response activated by cytokines, chemokines, growth factors, and mediated by free radicals, calcium overload leading to mitochondrial dysfunction. Secretory phospholipases (sPLA2) are a group of pro-inflammatory molecules associated with diseases such as atherosclerosis, which increase the risk of reperfusion injury. This acute response leads to breakdown of phospholipids such as cardiolipin, found in the mitochondrial inner membrane, leading to disruption of energy producing enzymes of the electron transport chain. Thus the activation of secretory phospholipases has a direct link to the vascular occlusion and arrhythmia observed in myocardial reperfusion injury. Therapeutic agents targeting sPLA2 are under human trials and many are in the preclinical phase. This article reviews the pathological effects of various groups of secretory phospholipases (I, II, V and X) implicated in myocardial ischemia reperfusion injury and the phospholipase inhibitors under development. Considering the fact that human trials in this class of drugs is limited, sPLA2 as a potential target for drug develo...Continue Reading

References

Sep 1, 1993·Journal of Molecular and Cellular Cardiology·L HarrisN A Shaikh
Jul 11, 1997·The Journal of Biological Chemistry·J A Tischfield
Sep 26, 1997·Journal of Lipid Mediators and Cell Signalling·J V Bonventre
Jul 23, 1999·Annals of the New York Academy of Sciences·R A Gottlieb, R L Engler
Jan 1, 2000·Cardiovascular Research·J E JordanJ Vinten-Johansen
May 18, 2001·American Journal of Physiology. Heart and Circulatory Physiology·L J De WindtM Van Bilsen
Oct 24, 2002·Journal of Molecular and Cellular Cardiology·Rakesh C Kukreja
Jun 14, 2003·American Journal of Physiology. Heart and Circulatory Physiology·R NijmeijerH W M Niessen
Sep 11, 2004·Biochemical and Biophysical Research Communications·Kevin M LawrenceDavid S Latchman
Nov 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eun Jin JoYoe-Sik Bae
Jul 12, 2005·Biochemical and Biophysical Research Communications·Ha Young LeeYoe-Sik Bae
Oct 4, 2005·Journal of the American College of Cardiology·Ziad MallatAlain Tedgui
Jan 5, 2006·Cellular and Molecular Neurobiology·Miriam KolkoNicolas G Bazan
May 3, 2006·Biochimica Et Biophysica Acta·María A Balboa, Jesús Balsinde
May 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Scott LevickLindsay Brown
Jun 22, 2006·Cardiovascular & Hematological Disorders Drug Targets·Paul A J KrijnenHans W M Niessen
Jan 6, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Meredith A BostromNancy R Webb
Oct 12, 2007·Biochimica Et Biophysica Acta·Susheel Gundewar, David J Lefer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.